NIDDM has a strong genetic component, as evidenced by the high level of concordance between identical twins. The nature of the genetic predisposition has remained largely unknown. Recently, the glucokinase gene locus on chromosome 7p has been shown to be linked to a subtype of NIDDM known as MODY in French and British pedigrees, and glucokinase mutations have been identified. To study the relationship between the glucokinase gene and NIDDM, we performed a linkage analysis in 12 Caucasian pedigrees ascertained through a proband with classical NIDDM. The LINKAGE program was used under four models, including autosomal dominant and recessive, with individuals with glucose intolerance counted as either affected or of unknown status. Linkage was significantly rejected with the dominant models (LOD scores -4.65, -4.25), and was unlikely with the recessive model when glucose intolerance was considered as affected (LOD score -1.38). These findings suggest that mutations in or near the glucokinase gene are unlikely to be the major cause of the inherited predisposition to NIDDM in Caucasian pedigrees, but do not exclude a role for this locus with a polygenic model, or a major role in some pedigrees.
A major genetic predisposition to NIDDM is suggested by the high level of concordance between identical twins (1, 2) . The nature of the putative gene defect is unknown (3) . The glucokinase gene has been proposed as a candidate for the inherited component of NIDDM (4, 5) . Glucokinase is expressed in liver and pancreatic p-cells and plays a key role in the regulation of glucose metabolism in these tissues (4) . It has been described as the pancreatic glucose sensor because of its role in glucose recognition and the stimulation of insulin synthesis and secretion (4, 6) . Glucokinase phosphorylates glucose to produce glucose-6-phosphate in the first metabolic step for glucose within the cell. Expression of the enzyme is increased by glucose in the pancreas and by insulin in the liver (7) .
Linkage between the glucokinase locus on chromosome 7p and diabetes has been reported in French pedigrees and a British pedigree with MODY, a subtype of NIDDM characterized by monogenic autosomal dominant transmission and early age of onset (<25 yr) (8, 9) . A nonsense mutation (codon 279 C-T, exon 7) (10) and a missense mutation (codon 299 G-C, exon 8) (11) of the gene have been identified in diabetic subjects in these pedigrees, providing strong evidence that mutations in this gene cause the diabetes in affected family members. Clinical studies of affected individuals in one pedigree suggest that glucokinase defects result in mild, predominantly early-onset NIDDM that is characterized by impaired p-cell function, with gestational diabetes occurring in affected females (9) . The early stages of the disease may only be disclosed when younger family members are tested. Clinical presentation as classical NIDDM can occur, although the disease can remain undetected until the 8th decade of life. These features raise the possibility that glucokinase defects may be a common cause of NIDDM. By using two DNA microsatellite polymorphisms near the glucokinase locus and linkage analysis, we investigated the relationship of the glucokinase gene with NIDDM in Caucasian pedigrees.
RESEARCH DESIGN AND METHODS
Our protocol was approved by the Central Oxford Research and Ethics Committee, and informed consent was obtained from all participants. Twenty Caucasian pro- bands with NIDDM were ascertained, and their firstdegree relatives (parents, siblings, and offspring) were characterized clinically. Of the 20 probands, 12 were heterozygous for a microsatellite polymorphism at the glucokinase locus, and these pedigrees were genotyped. The pedigrees are shown in Fig. 1 , and Table 1 gives details of the probands. Diagnosis. The first-degree relatives were screened with a 5 mg • kg ideal body weight" 1 • min" 1 continuous glucose infusion (CIGMA) test (n = 51) (12). The achieved plasma glucose level refers to the mean of the 50-, 55-, and 60-min samples obtained during the infusion. Where glucose tolerance testing was not possible, fasting plasma glucose samples were obtained {n = 23).
The following subjects were considered affected: 1) those with diabetes diagnosed according to WHO criteria who were using oral hypoglycemic agents, insulin, or specific diet therapy; 2) those with fasting hyperglycemia, with a fasting plasma glucose concentration >6.0 mM, which is >3 SDs above the mean of a normal, nondiabetic population (13) and has been used in previous studies (9, 14) ; 3) those with glucose intolerance, defined as fasting plasma glucose <6.0 mM, with an achieved plasma glucose level >2 SDs above the mean of an age-and obesity-matched nondiabetic population. The sensitivity and specificity of this criterion for the diagnosis of WHO-defined IGT has been demonstrated (15) .
The following subjects were classified as status unknown: subject III 3 in family J4, who had a history of acute pancreatitis before diabetes onset at age 34 yr, and subject III 2 in family J3, who had a fasting plasma glucose between 5.5 and 6.0 mM (5.8 mM) and did not have a glucose tolerance test. DNA studies. DNA was extracted from blood samples by using standard phenol/chloroform methods (15) . Two polymorphic dinucleotide repeat elements were investigated. The first (GCK-1) is located 10 kb 3' to the human glucokinase gene (17) . Three alleles were detected (designated as 1, 2, and 3, corresponding to z + 4, z + 2, and z) (17) . These were identified by performing a PCR with 0.05 ixmol of oligonucleotides 9509 (5'-TTGGT CAGTGTAGGCTGAACTCATG-3') and 9510 (5'-CCCA CACCAAAACTGCCTGTATTAG-3') in 50 \L\ reaction volumes containing 0.5 |xg of DNA, 100 [ig of each dNTP, 10 mM Tris HCI(pH 8.3), 50 mM KCI, 1.5 mM MgCI 2 , and 3 U of Amplitaq DNA polymerase (Perkin-Elmer Cetus). The PCR was performed by initially denaturing for 3 min at 94°C then using 40 cycles of 15 s at 94°C, 15 s at 55°C, and 20 s at 72°C. Six JJLI of the final product was electrophoresed on a 10% polyacrylamide gel at 100 V for 24 h, and bands were detected by ethidium bromide staining.
A second microsatellite (GCK-3), located in intron 1 of the human glucokinase gene, was examined (M. Stoffel, K. Xiang, J. Takeda, S. Nishi, and G.I. Bell, unpublished observations). GCK-3 was detected by PCR using the above conditions with the primers hGK-CA-1 (5'-AACA GATACGCTTCATCCTG-3') and hGK-CA-2 (5'-TGTCTG CAACTTACTCTTAC-3'). Four alleles for this locus were detected in our pedigrees. Linkage analysis. Because the mode of inheritance of NIDDM is uncertain (18), we performed linkage analysis with version 5.1 of the LINKAGE (19) computer programs under both autosomal dominant and autosomal recessive models. The numbers of affected sibling pairs with fully informative parents were insufficient for sibling pair analysis (20) . The analyses were performed with the 5 subjects with glucose intolerance considered as affected, and also with these subjects considered as status unknown. The putative gene frequency was fixed at 0.05 for the autosomal dominant model and at 0.25 for the recessive model, based on prevalence studies in a Caucasian population (21) . Four liability classes were defined on the basis of age as follows: class 1, >60 yr; class 2, 40-60 yr; class 3, 20-40 yr; class 4, <20 yr. The penetrance factors used for the heterozygous dominant genotype and for the homozygous recessive genotype were 0.90, 0.75, 0.45, and 0.15 respectively. These factors were derived from age-specific incidence figures, with the maximum figure derived from concordance in identical-twin studies (1,2). The penetrance factors used for the homozygous dominant genotype in each liability class were 0.95, 0.90, 0.90, and 0.80, respectively. To accommodate for potential heterogeneity, phenocopy rates were used for each liability class (0.01, 0.001, 0.0001, and 0.0001 respectively), and these rates were used as the penetrance factors for the heterozygous recessive genotype. The LOD scores also were calculated using higher phenocopy rates (0.05, 0.01, 0.001, and 0.0001). The allele frequencies used for GCK-1 were 0.24, 0.09, 0.66, and 0.01 for alleles 1-4, respectively, as determined in the CEPH pedigrees (17) . The allele frequencies used for alleles 1-4 of GCK-3 were 0.32, 0.62, 0.02, and 0.02. The recombination fraction between GCK-1 and GCK-3 was assumed to be 0. As a candidate gene was being examined, the LOD scores were calculated with the recombination fraction (6) between affection status and the glucokinase locus equal to 0.
RESULTS
The pedigrees and glucokinase genotypes for the families are shown in Fig. 1 . Table 2 shows the LOD scores for each model by pedigree at 9 = 0. Under the dominant models, the LOD scores significantly rejected linkage at a recombination fraction 6 = 0, with cumulative negative scores of <2. Under the recessive models, when the glucose intolerant subjects were considered affected, the cumulative LOD score indicated that linkage was unlikely (-1.38), however, linkage was not excluded when the glucose intolerant subjects were considered as status unknown (LOD score -0.29). When the phenocopy rates were increased to 0.05, 0.01, 0.001, and 0.0001 for the liability classes, the cumulative LOD scores for the dominant model with and without glucose intolerance considered as affected were -4.44 and -4.27, respectively, and -1.04 and -0.38 for the recessive models, respectively.
DISCUSSION
Linkage has been demonstrated between the glucokinase gene and MODY (8, 9) , and mutations have been characterized (10, 11) . These data indicate that glucokinase gene mutations can cause dominantly inherited early-onset NIDDM, which may present clinically in old age. The current data suggest that glucokinase mutations are unlikely to act as the major locus in the predisposition to classical NIDDM in most Caucasian pedigrees, although we cannot exclude a role for this locus under a polygenic model, or a major role in some pedigrees. Linkage analysis in pedigrees is a powerful tool for examining the role of candidate genes in the etiology of inherited diseases with a defined mode of transmission (22) . The mode of inheritance of NIDDM is uncertain. Two inheritance models were tested in this study, and the erroneous rejection of the hypothesis that glucokinase mutations are the major determinants of NIDDM risk is unlikely. However, if NIDDM were polygenic with multiple predisposing loci, linkage with glucokinase may not be detected, despite a significant role for the gene.
Heterogeneity is often considered likely in NIDDM and may occur within, as well as between, pedigrees (11) . A role for glucokinase mutations is possible under a heterogeneous model. The statistical power was insufficient to demonstrate formally or exclude linkage in any individual pedigree in this study. Pedigrees J3 and J4 had positive but not statistically significant LOD scores with the dominant inheritance model ( Table 2 ). The molecular scanning technique of single strand conformation polymorphism analysis (23) and the direct sequencing of the glucokinase gene exons and promoter region are being undertaken in pedigrees J3 and J4, and in individual patients with NIDDM, to evaluate whether mutations of this gene occur in some subjects with classical NIDDM.
In conclusion, the demonstration of nonlinkage of the glucokinase gene with NIDDM in 12 Caucasian families makes it unlikely that mutations of this gene are the major cause of genetic susceptibility to NIDDM in Caucasian subjects. The role of glucokinase defects in NIDDM in non-Caucasian pedigrees remains to be explored.
